Browse

Concurrent pulsed high-intensity focused ultrasound and gemcitabine treatment in animal models of pancreatic cancer
췌장암 동물 모델에서 고강도 집속 초음파와 Gemcitabine 병용 요법의 효과에 대한 연구

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
이은선
Advisor
이재영
Major
의과대학 의학과
Issue Date
2013-02
Publisher
서울대학교 대학원
Keywords
고강도 집속 초음파췌장암Gemcitabine동물 연구
Description
학위논문 (박사)-- 서울대학교 대학원 : 의학과 영상의학 전공, 2013. 2. 이재영.
Abstract
Introduction: We sought to investigate whether concurrent exposure to pulsed high-intensity focused ultrasound (HIFU) and the chemotherapeutic drug gemcitabine could enhance apoptosis in pancreatic cancer.

Methods: A pancreatic cancer xenograft model was established using BALB/c nude mice and human pancreatic cancer cells (PANC-1). In the first study, mice were randomly allocated into one of the following four groups: control (n = 4), HIFU alone (n = 4), gemcitabine alone (GEM) (n = 28), and concurrent treatment of HIFU with gemcitabine (HIGEM) (n = 28). The GEM and HIGEM groups were subdivided into four subgroups according to the injected drug dose (50 - 200 mg/kg) in 16 mice and another four subgroups according to the time interval between drug injection and HIFU treatment in 16 mice (each subgroup, n = 4). Apoptotic ratios were evaluated using the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay and percentage of necrosis, as evaluated with Harris hematoxylin solution and eosin Y (H & E) staining, three days after treatment. The second study was performed to evaluate tumor growth rates of the four groups. Each group was treated weekly for three weeks, and the tumor size was periodically measured for up to four weeks from the beginning of treatment.

Results: In the first study, the overall apoptotic ratios in the HIGEM group were significantly higher than the GEM group (p = 0.02). In a subgroup analysis, HIGEM was superior to GEM in generating apoptosis when 150-200 mg/kg gemcitabine and short-term intervals less than 2 hours were used (p = 0.01). In the second study, HIGEM treatment exhibited the slowest tumor growth. However, despite a visible distinction, no statistically significant difference was found between HIGEM and GEM groups (p > 0.05).

Conclusion: Treatment with both HIFU and gemcitabine might enhance cell apoptosis and reduce tumor growth in pancreatic carcinoma. For this concurrent treatment, high dosage of gemcitabine with a short-term delay would be recommended to maximize therapeutic effect.
Language
English
URI
https://hdl.handle.net/10371/121875
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)Theses (Ph.D. / Sc.D._의학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse